MX2022000801A - Composicion y metodo para prevenir, aliviar o tratar lesion del higado. - Google Patents

Composicion y metodo para prevenir, aliviar o tratar lesion del higado.

Info

Publication number
MX2022000801A
MX2022000801A MX2022000801A MX2022000801A MX2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A MX 2022000801 A MX2022000801 A MX 2022000801A
Authority
MX
Mexico
Prior art keywords
preventing
composition
alleviating
liver injury
treating liver
Prior art date
Application number
MX2022000801A
Other languages
English (en)
Inventor
Gwang Pyo Ko
Bo - Ram Cho
Hyun Ju You
Won Kim
Giljae Lee
Original Assignee
Kobiolabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200087105A external-priority patent/KR20210014576A/ko
Application filed by Kobiolabs Inc filed Critical Kobiolabs Inc
Priority claimed from KR1020200095361A external-priority patent/KR102395036B1/ko
Publication of MX2022000801A publication Critical patent/MX2022000801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/26—Klebsiella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/36—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Actinomyces; from Streptomyces (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La presente invención se relaciona a una composición para prevenir, aliviar o tratar la lesión de hígado, por ejemplo, hígado graso no alcohólico, y más específicamente, se relaciona a una composición para prevenir o tratar la lesión de hígado que comprende una cepa de Ruminococcus spp.
MX2022000801A 2019-07-30 2020-07-30 Composicion y metodo para prevenir, aliviar o tratar lesion del higado. MX2022000801A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190092689 2019-07-30
KR1020200087105A KR20210014576A (ko) 2019-07-30 2020-07-14 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 그의 예방 또는 치료용 약학적 조성물
PCT/KR2020/010097 WO2021020923A1 (ko) 2019-07-30 2020-07-30 간 손상 예방, 개선, 또는 치료용 조성물 및 간 손상 예방, 개선, 또는 치료방법
KR1020200095361A KR102395036B1 (ko) 2019-07-30 2020-07-30 비알코올성 지방간 질환의 예측 또는 진단용 키트, 및 진단방법
KR1020200094922A KR102401535B1 (ko) 2019-07-30 2020-07-30 간 손상 예방, 개선, 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2022000801A true MX2022000801A (es) 2022-02-16

Family

ID=74228956

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022000802A MX2022000802A (es) 2019-07-30 2020-07-30 Kit para predecir o diagnosticar enfermedad de higado graso no alcoholico, y metodo para diagnosticar enfermedad de higado graso no alcoholico.
MX2022000801A MX2022000801A (es) 2019-07-30 2020-07-30 Composicion y metodo para prevenir, aliviar o tratar lesion del higado.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022000802A MX2022000802A (es) 2019-07-30 2020-07-30 Kit para predecir o diagnosticar enfermedad de higado graso no alcoholico, y metodo para diagnosticar enfermedad de higado graso no alcoholico.

Country Status (7)

Country Link
US (2) US20220257669A1 (es)
JP (3) JP7499841B2 (es)
AU (2) AU2020320244B2 (es)
BR (2) BR112022001602A2 (es)
CA (2) CA3148434A1 (es)
MX (2) MX2022000802A (es)
WO (2) WO2021020920A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205651A2 (en) * 2022-04-19 2023-10-26 Cedars-Sinai Medical Center Methods of treating and diagnosing fatty liver disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538893A (ja) 2005-04-28 2008-11-13 国立大学法人高知大学 脂質代謝不全の検出方法、及びそれに使用する検査薬
JP4918674B2 (ja) 2005-06-15 2012-04-18 国立大学法人 東京医科歯科大学 非アルコール性脂肪肝の治療薬のスクリーニング方法
AU2010224587A1 (en) * 2009-03-17 2011-09-22 Axcan Pharma, Inc. Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid
CN107847531A (zh) * 2015-05-21 2018-03-27 耶达研究及发展有限公司 用于促进健康的细菌群
JP2019517783A (ja) 2016-04-20 2019-06-27 ヒューマン ロンジヴィティ，インコーポレイテッド 肝疾患を検出するためのマイクロバイオーム（ｍｉｃｒｏｂｉｏｍｅ）プロファイルの使用
BR112018074452A2 (pt) * 2016-06-03 2019-03-19 Chemocentryx, Inc. método de tratamento de fibrose hepática
WO2018065132A1 (en) * 2016-10-04 2018-04-12 Institut National De La Recherche Agronomique Use of ahr agonist for the preventive or curative treatment of metabolic syndrome and the associated disorders.
IT201600109507A1 (it) * 2016-10-28 2018-04-28 Probiotical Spa Composizione per il trattamento preventivo o curativo dei disturbi epatici
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP6799230B2 (ja) 2017-01-12 2020-12-16 ビオフェルミン製薬株式会社 非アルコール性脂肪性肝疾患の診断方法、又は診断用キット
WO2019118515A2 (en) * 2017-12-11 2019-06-20 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms

Also Published As

Publication number Publication date
AU2020323825B2 (en) 2024-05-09
WO2021020920A3 (ko) 2021-03-25
BR112022001637A2 (pt) 2022-03-22
WO2021020920A2 (ko) 2021-02-04
JP7303372B2 (ja) 2023-07-04
JP2022542944A (ja) 2022-10-07
AU2020323825A1 (en) 2022-03-17
CA3148431A1 (en) 2021-02-04
JP2022542506A (ja) 2022-10-04
JP7499841B2 (ja) 2024-06-14
BR112022001602A2 (pt) 2022-03-22
JP2024056699A (ja) 2024-04-23
WO2021020923A1 (ko) 2021-02-04
US20220276246A1 (en) 2022-09-01
US20220257669A1 (en) 2022-08-18
CA3148434A1 (en) 2021-02-04
AU2020320244A1 (en) 2022-03-17
AU2020320244B2 (en) 2024-10-10
MX2022000802A (es) 2022-02-16

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
JOP20210060A1 (ar) معدلات لمضاد تريبسين ألفا-1
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2020012754A (es) Procesos para mejorar el crecimiento y la productividad de la levadura.
MX2018003158A (es) Composicion bioactiva para mejorar la tolerancia al estres de las plantas.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2021003170A (es) Moduladores de la expresion de pnpla3.
EP3842515A4 (en) NOVEL STRAIN OF CUTIBACTERIUM GRANULOSUM, AND COMPOSITION COMPRISING SUCH STRAIN OR CULTURE OF SUCH STRAIN FOR PREVENTING OR TREATING ACNE
PH12020551995A1 (en) Modulator of apol1 expression
ZA201904387B (en) Compositions and methods for treating, ameliorating and preventing h. pylori
WO2018127612A3 (en) Compositions comprising lespedeza plant extract
SG11201901752RA (en) Method for improving aftertaste of alcoholic beverages using allulose
MX2021001520A (es) Metodos para retardar la ocurrencia de diabetes tipo 2 de nuevo inicio y para desacelerar el progreso de y tratamiento de la diabetes tipo 2.
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MX2021010346A (es) Composicion que contiene extracto derivado de plantas y/o producto procesado derivado de plantas.
MX2021004467A (es) Productos lacteos filtrados acidos reducidos en carbohidratos.
CR20210668A (es) Complejos macromoleculares fungicidas de ditiocarbamat
CO2022004699A2 (es) Composición mejorada
MX2021005758A (es) Moduladores de la expresión de irf5.
MX2022000801A (es) Composicion y metodo para prevenir, aliviar o tratar lesion del higado.
MX2018013538A (es) Productos de zumo y métodos para reducir el oscurecimiento enzimático.
MX2021003598A (es) Microorganismos para la inhibicion de patogenos vegetales.
WO2019098811A3 (ko) Chp(시클로-히스프로)를 포함하는 골 손실 질환의 예방, 개선 또는 치료용 조성물
EP4005578A4 (en) COMPOSITION AND METHODS FOR PREVENTING, RELIEVING OR TREATING LIVER INJURY